Core Insights - Artelo Biosciences, Inc. has successfully closed a public offering of 441,210 shares of common stock at a price of $4.40 per share, along with pre-funded warrants for an additional 13,335 shares at $4.399 each, generating approximately $2.0 million in gross proceeds before expenses [1][2]. Offering Details - The offering included a 45-day option for underwriters to purchase up to an additional 68,181 shares to cover over-allotments [2]. - The shares and warrants were offered under a "shelf" registration statement filed with the SEC, which became effective on July 14, 2023 [3]. - The final prospectus supplement and accompanying base prospectus were filed with the SEC on October 1, 2025 [4]. Company Overview - Artelo Biosciences is a clinical-stage pharmaceutical company focused on developing treatments that modulate lipid-signaling pathways for various conditions, including cancer, pain, and dermatologic issues [7]. - The company aims to address significant unmet medical needs through a diversified pipeline and is led by an experienced executive team [7].

Core Points - Artelo Biosciences, Inc. has announced the pricing of its public offering of 441,210 shares of common stock at $4.40 per share and pre-funded warrants at $4.399 per warrant, aiming for gross proceeds of approximately $2.0 million [1] - The offering is managed by R.F. Lafferty & Co., Inc. and is conducted under a "shelf" registration statement filed with the SEC [2] - The offering is expected to close on October 1, 2025, pending customary closing conditions [1] Company Overview - Artelo Biosciences is a clinical-stage pharmaceutical company focused on developing treatments that modulate lipid-signaling pathways for conditions such as cancer, pain, and dermatologic issues [6] - The company has a diversified pipeline addressing significant unmet medical needs, including anorexia, anxiety, and inflammation [6] - Artelo is led by an experienced executive team and collaborates with world-class researchers and digital-asset technology partners to maximize stakeholder value [6]

Core Insights - Artelo Biosciences, Inc. presented interim data from its Phase 2 Cancer Appetite Recovery Study (CAReS) for ART27.13, showing significant improvements in weight, lean body mass, and daily activity in patients with cancer anorexia-cachexia syndrome (CACS) [1][2][4] Summary by Sections Interim Data Highlights - Patients treated with the highest dose of ART27.13 (1300 µg) achieved an average weight gain of +6% over 12 weeks, while placebo patients lost approximately 5% [7] - Improvements in lean body mass were consistent with total weight gains, indicating muscle preservation or accrual [7] - Digital wearable data confirmed that treated patients exhibited greater daily activity metrics compared to placebo [7] - ART27.13 maintained a favorable safety profile, with adverse events primarily mild to moderate and no serious drug-related events reported [7][8] About ART27.13 - ART27.13 is a novel benzimidazole derivative and dual cannabinoid agonist, designed for once-daily oral administration, targeting peripheral CB1 and CB2 receptors [6] - The drug aims to improve body weight, appetite, muscle degeneration, and quality of life in cancer patients [6] - Previous studies have shown a statistically significant and dose-dependent increase in body weight in healthy individuals with back pain [6] About CAReS - The CAReS study is a Phase 1/2 randomized, placebo-controlled trial assessing ART27.13 in patients with cancer anorexia and weight loss [9] - Anorexia and weight loss in cancer patients can lead to weakened immune systems and increased discomfort, with a weight loss of over 5% predicting poorer outcomes [9][10] - The Phase 2 stage aims to evaluate ART27.13's effectiveness in improving lean body mass, weight gain, and anorexia compared to placebo [9] Market Opportunity - CACS affects up to 80% of patients with advanced cancer, representing a market opportunity exceeding $3 billion [10] - Currently, there are no FDA-approved treatments for cancer anorexia-cachexia syndrome in the US, UK, or EU [10] Company Overview - Artelo Biosciences is focused on developing therapeutics that modulate lipid-signaling pathways, addressing significant unmet needs in various conditions including anorexia and cancer [11] - The company collaborates with world-class researchers and applies rigorous scientific and regulatory practices to maximize stakeholder value [11]

Core Insights - Premarket trading is showing notable activity with significant price movements indicating potential trading opportunities before the market opens [1] Premarket Gainers - 89bio, Inc. (ETNB) increased by 83% to $14.84 [3] - Aptevo Therapeutics Inc. (APVO) rose by 75% to $2.47 [3] - Psyence Biomedical Ltd. (PBM) saw a 29% increase to $4.82 [3] - Beam Global (BEEM) gained 27% reaching $3.23 [3] - MicroAlgo Inc. (MLGO) was up 14% at $13.06 [3] - Akero Therapeutics, Inc. (AKRO) increased by 12% to $47.50 [3] - Hyperion DeFi, Inc. (HYPD) rose by 11% to $13.69 [3] - Sonnet BioTherapeutics Holdings, Inc. (SONN) increased by 11% to $7.85 [3] - FuelCell Energy, Inc. (FCEL) was up 9% at $8.34 [3] - Robo.ai Inc. (AIIO) gained 6% to $2.05 [3] Premarket Losers - Presidio Property Trust, Inc. (SQFT) decreased by 14% to $7.58 [4] - Aeluma, Inc. (ALMU) fell by 10% to $15.18 [4] - FGI Industries Ltd. (FGI) dropped 10% to $7.65 [4] - Lazydays Holdings, Inc. (GORV) was down 9% at $2.26 [4] - StableX Technologies, Inc. (SBLX) decreased by 8% to $5.40 [4] - Artelo Biosciences, Inc. (ARTL) fell by 8% to $4.48 [4] - SciSparc Ltd. (SPRC) decreased by 8% to $4.10 [4] - Cracker Barrel Old Country Store, Inc. (CBRL) was down 7% at $45.75 [4] - Columbus Circle Capital Corp I (BRR) fell by 7% to $9.42 [4] - Visionary Holdings Inc. (GV) decreased by 7% to $2.58 [4]

Core Insights - Artelo Biosciences, Inc. announced new preclinical data on ART12.11, a proprietary cocrystal of cannabidiol and tetramethylpyrazine, showing significant improvements over conventional CBD in treating stress-induced depression and anxiety [1][2][4] Group 1: Study Findings - The peer-reviewed study demonstrated that ART12.11 significantly outperformed CBD alone in reducing symptoms of stress-induced depression and anxiety, while also achieving superior oral bioavailability [2][4] - ART12.11 reversed stress-induced behavioral deficits and produced robust anti-depressant and anxiolytic-like effects, superior to CBD alone, TMP alone, or a non-crystalline mixture of CBD and TMP [7] - Mechanistic insights revealed that ART12.11 enhances activation of endocannabinoid and serotonergic systems in brain regions critical to mood regulation, suggesting a selective influence that maximizes therapeutic benefits while minimizing side effects [5][7] Group 2: Regulatory and Developmental Aspects - The UK regulatory authority, MHRA, has agreed that Artelo may rely on existing nonclinical and clinical evidence for CBD and leverage legacy data for TMP, which is expected to streamline the development plan for ART12.11 [5][6] - The guidance from MHRA is anticipated to reduce costs and enable rapid advancement towards the proposed first human study with ART12.11 planned for next year [5][6] Group 3: Company Overview - Artelo Biosciences is focused on developing proprietary therapeutics that modulate lipid-signaling pathways, addressing significant unmet needs in various medical conditions [8] - The company has adopted a digital asset treasury strategy, designating Solana as a core reserve asset to enhance liquidity management and long-term value creation [8]

Core Viewpoint - Artelo Biosciences, Inc. has successfully closed a public offering of common stock and pre-funded warrants, raising approximately $3.0 million to support its clinical-stage pharmaceutical initiatives focused on lipid-signaling pathways for various medical conditions [1][2]. Group 1: Offering Details - The company offered 640,924 shares of common stock at a public price of $4.40 per share and pre-funded warrants to purchase up to 40,894 shares at a price of $4.399 per warrant [1]. - The gross proceeds from the offering were approximately $3.0 million before deducting underwriting discounts and other expenses [2]. - Underwriters were granted a 45-day option to purchase an additional 102,272 shares at the public offering price to cover over-allotments [2]. Group 2: Regulatory and Documentation - The shares and warrants were offered under a "shelf" registration statement on Form S-3, which was filed with the SEC on July 6, 2023, and declared effective on July 14, 2023 [3]. - The final prospectus supplement and accompanying base prospectus were filed with the SEC on September 5, 2025, and are available on the SEC's website [4]. Group 3: Company Overview - Artelo Biosciences is a clinical-stage pharmaceutical company focused on developing therapeutics that modulate lipid-signaling pathways, addressing significant unmet needs in various medical conditions including cancer and pain [7]. - The company has adopted a corporate finance initiative to deploy excess capital into digital assets as part of its treasury strategy [7].

Company Performance - Neonode Inc. experienced a stock price drop of approximately 68.34%, closing at $6.81, down from a year high of $29.9, influenced by market reactions to company developments and industry trends [2][8] - Artelo Biosciences saw a 50.34% decrease in its stock price, closing at $4.35, amid ongoing clinical trials and a public offering priced at $3 million [3][8] - 707 Cayman Holdings Limited faced a 48.45% decline in its stock price to $0.39, potentially due to challenges in the retail sector and exploring a crypto treasury reserve with Precious Choice Global Limited [4][8] - Aethlon Medical's stock price fell by 45.76% to $0.73, possibly linked to recent performance updates and investor sentiment towards the healthcare sector, with a public offering valued at $4.5 million [5] - Purple Biotech's stock price decreased by 43.54%, closing at $0.80, which may be related to clinical trial results and market conditions affecting biotech firms [6] Market Trends - The significant price movements of these companies highlight the importance of monitoring market trends, company developments, and broader economic factors that can impact stock performance [7]

Core Viewpoint - Artelo Biosciences, Inc. has announced a public offering of common stock and pre-funded warrants, aiming to raise approximately $3.0 million to support its clinical-stage pharmaceutical initiatives focused on treating various medical conditions [1][6]. Group 1: Offering Details - The company is offering 640,924 shares of common stock at a price of $4.40 per share and pre-funded warrants to purchase up to 40,894 shares at a price of $4.399 per warrant [1]. - The total gross proceeds from the offering are expected to be around $3.0 million before deducting underwriting discounts and other expenses [1]. - Underwriters have a 45-day option to purchase an additional 102,272 shares to cover over-allotments [1]. Group 2: Underwriting and Registration - R.F. Lafferty & Co., Inc. is acting as the sole book-running manager for the offering [2]. - The shares and warrants are being offered under a "shelf" registration statement filed with the SEC, which was declared effective on July 14, 2023 [2]. Group 3: Company Overview - Artelo Biosciences is a clinical-stage pharmaceutical company focused on developing treatments that modulate lipid-signaling pathways for conditions such as cancer, pain, and dermatologic issues [6]. - The company is also implementing a digital asset treasury strategy to enhance its financial position [6].

Core Viewpoint - Artelo Biosciences, Inc. has announced the commencement of an underwritten public offering of its common stock and/or pre-funded warrants, aimed at raising capital for its clinical-stage pharmaceutical developments [1] Company Overview - Artelo Biosciences, Inc. is a clinical-stage pharmaceutical company focused on developing treatments that modulate lipid-signaling pathways for various conditions including cancer, pain, and dermatologic issues [1][6] - The company has a diversified pipeline addressing significant unmet medical needs in areas such as anorexia, cancer, anxiety, dermatologic conditions, pain, and inflammation [6] - Artelo is also implementing a digital asset treasury strategy, deploying excess capital into Solana [6] Offering Details - The offering is being managed by R.F. Lafferty & Co., Inc. as the sole book-running manager [2] - The shares are being offered under a "shelf" registration statement filed with the U.S. Securities and Exchange Commission (SEC) [2] - A prospectus supplement detailing the terms of the public offering will be filed with the SEC [3] Additional Information - Copies of the prospectus supplement and accompanying prospectus will be available on the SEC's website and from R.F. Lafferty & Co., Inc. [4] - The press release clarifies that it does not constitute an offer to sell or solicit offers to buy any of the securities described [5] - For investor relations, Crescendo Communications, LLC is the contact point [8]

Core Insights - Artelo Biosciences, Inc. is positioned to secure a development partner for ART27.13 based on positive interim results from its Phase 2 CAReS trial for cancer anorexia-cachexia syndrome (CACS) [1][4] - The interim results show significant improvements in weight, lean body mass, and activity in patients treated with ART27.13 [2] - Artelo does not foresee the need for internal funding for a Phase 3 trial, indicating a preference for a licensing transaction to maximize shareholder value [3] Company Overview - Artelo Biosciences is a clinical-stage pharmaceutical company focused on developing treatments that modulate lipid-signaling pathways for various conditions, including cancer and pain [8] - ART27.13 is a novel benzimidazole derivative aimed at improving body weight, appetite, and quality of life in cancer patients, with a strong safety profile demonstrated in previous studies [5] - The company has a diversified pipeline addressing significant unmet medical needs and is also engaging in digital asset treasury strategies [8] Clinical Trial Insights - The CAReS trial is a Phase 1/2 randomized, placebo-controlled study designed to evaluate ART27.13's effectiveness in treating cancer-related anorexia and weight loss [6] - CACS affects up to 80% of advanced cancer patients and represents a market opportunity exceeding $3 billion, with no current FDA-approved treatments available [7]